Search Results for: Virus

November 1, 2019November 1, 2019

High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis.

Publication date: Oct 01, 2019 The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with ... Read more

November 1, 2019November 1, 2019

Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study.

Multiple Sclerosis Literature

Publication date: May 02, 2019 Open Access PDF Lambrianides, S., Demetriou, C.A., Tillyris, A., Kkolou, E., Gaglia, E., Agkastinioti, E., Leonidou, E., Christou, Y.P., Papacostas, S.S., Kleopa, K.A., Kyriakides, T., ... Read more

October 30, 2019October 30, 2019

No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants.

Huntington's Disease Literature

Publication date: Oct 28, 2019 Gene therapy is emerging as an effective treatment option for various inherited genetic diseases. Gutless adenovirus (GLAd), also known as helper-dependent adenovirus (HDAd), has many ... Read more

October 25, 2019October 25, 2019

Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate.

Multiple Sclerosis Literature

Publication date: Jan 08, 2019 Progressive multifocal leukoencephalopathy (PML), a potentially fatal demyelinating disease caused by the John Cunningham virus (JCV), can occur as a complication of treatment with rituximab, ... Read more

October 25, 2019October 25, 2019

Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate.

Multiple Sclerosis Literature

October 22, 2019October 22, 2019

Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.

Melanoma Literature

Publication date: Oct 18, 2019 Virus-like vesicles (VLV) are infectious, self-propagating alphavirus-vesiculovirus hybrid vaccine vectors that can be engineered to express foreign antigens to elicit a protective immune response. VLV ... Read more

October 11, 2019October 11, 2019

Need to Know: MS and Respiratory Viruses

Multiple Sclerosis News

Publication date: Oct 10, 2019 If you have children or work in a public-facing job, then you will have already noted the onset of cold and flu season and the ... Read more

September 27, 2019September 27, 2019

Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine.

Melanoma Literature

Publication date: Sep 27, 2019 Interleukin-24 (IL-24) is a promising agent for cancer immunotherapy that induces apoptosis of tumor cells and enhances T cell activation and function. In order to ... Read more

September 14, 2019September 14, 2019

#ECTRIMS2019 – Human Herpesvirus 6A May Increase MS Risk, Study Suggests

Multiple Sclerosis News

Publication date: Sep 13, 2019 In contrast, the IgG response against IE1B did not correlate with such risk in patients with established MS. -The A variant came out as extremely ... Read more

September 10, 2019September 10, 2019

Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-Like Particles.

Melanoma Literature

Publication date: Sep 09, 2019 Mucin-1 (MUC1) is a highly attractive antigenic target for anti-cancer vaccines. Naturally existing MUC1 can contain multiple types of O-linked glycans, including the Thomsen-Friedenreich (Tf) ... Read more